New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AbbVie Inc.

ABBV

Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.

Revenue
+10.3%
EPS
+2,270.0%
Free cash flow
+9.97%
Total debt
+17.7%

Quarter to September 2026, against a year earlier

288.54 5.03 +1.77%
Market cap
$501.2B
P/E
48.8×
Fwd P/E FY26e
37.6×
Dividend yield
2.44%
F-score
8/9
ROIC
20.2%
Net debt / EBITDA
2.6×
Payout ratio
1.2×

AbbVie Inc. (ABBV) EV/FCF

Alert me on EV/FCF

As of Nov 19, 2026, AbbVie Inc. (ABBV) trades at a EV/FCF of 30.3×. Over the past ten years it has ranged from 9.6× (March 2020) to 39.0× (January 2015); the current reading is higher than 96% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 26.2× 24.19%
FY2024 21.1× 41.32%
FY2023 14.9× 5.89%
FY2022 14.1× 1.07%
FY2021 13.9× (8.65%)
FY2020 15.3× 23.40%
FY2019 12.4× (9.28%)
FY2018 13.6× (30.38%)
FY2017 19.6× (2.41%)
FY2016 20.1× 17.54%

Quarterly newest first

Period EV/FCF Change
Sep 2026 28.2× 0.94%
Jun 2026 28.0× 24.64%
Mar 2026 22.4× (14.28%)
Dec 2025 26.2× 9.04%
43 more quarters

Against its own ten years

Low 9.6× High 39.0×
Ten-year median 16.6×
Current reading's percentile 99

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on ABBV